HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

Immobilized Anti-HLA-A*02:01&B2M&NY-ESO-1 Antibody, hFc Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human, His Tag with the EC50 of 9.0 ng/ml determined by ELISA.

HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

The purity of HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human was greater than 95% as determined by SEC-HPLC.

HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag captured on CM5 Chip via Protein A can bind HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human, His Tag with an affinity constant of 13.43 nM as determined in SPR assay (Biacore T200).

HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
Z06579
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer[Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQC peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQC		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 50.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS, 100mM L-arginine (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

    Immobilized Anti-HLA-A*02:01&B2M&NY-ESO-1 Antibody, hFc Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human, His Tag with the EC50 of 9.0 ng/ml determined by ELISA.

  • HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

    The purity of HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human was greater than 95% as determined by SEC-HPLC.

  • HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

    HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human

    Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag captured on CM5 Chip via Protein A can bind HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer, His & Avi, Human, His Tag with an affinity constant of 13.43 nM as determined in SPR assay (Biacore T200).


Background
Target Background NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
Synonyms MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.